Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$92.10M+25916.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Shannon
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 435
- Beta
- 0.84
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.20
Financials
Revenue
$92.10M+25916.9%Net Income
$-31.10MEBITDA
$-20.94MFree Cash Flow
$8.05MEPS (diluted)
$-0.18Shares Outstanding (diluted)
172.82M+8430.1%Operating Expenses
$71.70MCash & Debt
$121.75MReturn of Capital
$191.0KRevenue by Segment (annual)
$332.62MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $291.85M | $554.0K | $0.00 |
| 2024 | $203.07M | $-54.84M | $-0.37 |
| 2023 | $163.91M | $-62.26M | $-0.45 |
| 2022 | $110.25M | $-94.66M | $-0.70 |
| 2021 | $49.59M | $-122.72M | $-1.55 |
| 2020 | $20.43M | $-91.14M | $-2.14 |
| 2019 | $2.72M | $-125.58M | $-3.49 |
| 2018 | $2.46M | $-60.08M | $-4.99 |
| 2017 | $1.56M | $-26.55M | $-13.09 |
| 2016 | $1.07M | $-13.21M | $-7.17 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.01
- Implied price
- $0.09
- Return from $10.19
- -61.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.05 — -99.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -67.4% | -65.9% | -64.7% | -63.6% | -62.6% |
| 3.0% | -65.7% | -64.2% | -62.9% | -61.7% | -60.7% |
| 8.0% | -64.1% | -62.4% | -61.1% | -59.8% | -58.7% |
| 13.0% | -62.4% | -60.7% | -59.2% | -58.0% | -56.8% |
| 18.0% | -60.8% | -59.0% | -57.4% | -56.1% | -54.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (4)
- Newsreuters.com·11d ago·Neutral
Lundbeck expresses interest in buying Xeris, Bloomberg News reports Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported on Tuesday, citing people familiar with the matter.
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
View source ↗ - Newsbusinesswire.com·45d ago·Neutral
Xeris Announces Details for XP-8121 Program Overview Webinar CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company's Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidis…
View source ↗ - Newsseekingalpha.com·51d ago·Positive
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for XERS at midpoint, supporting a forward P/S ratio of ~3.4x and fair valuation. XP-8121, a once-weekly injectable levothyroxine, targets a $1B+ U.S. market and could be a future blockbuster pending Phase 3 trial initiation.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.03 per share
Typical surprise +38.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.18 vs $0.01miss
- Thu, May 7$0.01 vs $-0.00beat
- Mon, Mar 2$0.06 vs $0.03beat
- Thu, Nov 6$0.00 vs $0.01miss
- Thu, Aug 7$-0.01 vs $-0.03beat
- Thu, May 8$-0.06 vs $-0.07beat
Estimates and results for XERS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XERS officers and directors.
- Bought
- —
- Sold
- $6.9m
0 trades
37 trades
- Pieper Stevensold
- Mcculloch Kevinsold
- Hecht Bethsold
- Mcculloch Kevinsold
- Mcculloch Kevinsold
- Hecht Bethsold
- Pieper Stevensold
- Pieper Stevensold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in XERS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.